Nivolumab: tested in a combination
680 studies: another drug in the study is under test too. Page 6 of 7. Open to participants first (135), then studies with results posted, then the rest; newest registration first within each.
- A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDSWithdrawnNCT04044209Phase 2Report a problem
- Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLCActive, not recruitingNCT04043195Phase 1/2Report a problem
- Nivolumab and Ipilimumab in People With Aggressive Pituitary TumorsCompletedNCT04042753Phase 2Report a problem
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedNCT04039607Phase 3Report a problem
- The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic MelanomaStatus unknownNCT04017897Phase 2Report a problem
- Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04017650Phase 1/2Report a problem
- Adjuvant Treatment Determined By Pathological Response To Neoadjvuant NivolumabActive, not recruitingNCT04013854Phase 2Report a problem
- Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung CancerActive, not recruitingNCT04013542Phase 1Report a problem
- A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWithdrawnNCT04007588Phase 2Report a problem
- Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.Active, not recruitingNCT04006262Phase 2Report a problem
- Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal AdenocarcinomaStatus unknownNCT03995017Phase 1/2Report a problem
- Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaCompletedNCT03984357Phase 2Report a problem
- Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and ChemotherapyWithdrawnNCT03982121Phase 1Report a problem
- Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian CarcinomaCompletedNCT03959761Phase 1/2Report a problem
- Cryotherapy With in Situ Immunotherapy in Melanoma MetastasisCompletedNCT03949153Phase 1/2Report a problem
- Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCCCompletedNCT03939975Phase 2Report a problem
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural MesotheliomaActive, not recruitingNCT03918252Phase 2Report a problem
- Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaCompletedNCT03892044Phase 1Report a problem
- Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent GlioblastomaCompletedNCT03890952Phase 2Report a problem
- Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaActive, not recruitingNCT03884998Phase 1Report a problem
- A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate CancerStatus unknownNCT03879122Phase 2/3Report a problem
- An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid TumorsStatus unknownNCT03864575Phase 2Report a problem
- Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular CarcinomaCompletedNCT03841201Phase 2Report a problem
- NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerCompletedNCT03832621Phase 2Report a problem
- Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AMLStatus unknownNCT03825367Phase 1/2Report a problem
- An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)Status unknownNCT03823625Phase 2Report a problem
- Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual DiseaseActive, not recruitingNCT03818685Phase 2Report a problem
- Testing Immunotherapy Versus Observation in Patients With HPV Throat CancerActive, not recruitingNCT03811015Phase 3Report a problem
- Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerActive, not recruitingNCT03803553Phase 3Report a problem
- Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell CancerCompletedNCT03798639Phase 1Report a problem
- Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell LymphomaCompletedNCT03798314Phase 1Report a problem
- Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric CancerActive, not recruitingNCT03776487Phase 2Report a problem
- Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaCompletedNCT03770416Phase 2Report a problem
- Nivolumab With Vismodegib in Patients With Basal Cell Nevus SyndromeWithdrawnNCT03767439Phase 2Report a problem
- Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated GlioblastomaActive, not recruitingNCT03743662Phase 2Report a problem
- An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03735628Phase 1Report a problem
- ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerCompletedNCT03732664Phase 1Report a problem
- Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of MelanomaTerminatedNCT03728465Phase 2Report a problem
- Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerCompletedNCT03728361Phase 2Report a problem
- RACIN in Patients With Advanced TIL-negative Solid TumorsCompletedNCT03728179Phase 1Report a problem
- Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal CancerCompletedNCT03712943Phase 1Report a problem
- An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnNCT03704077Phase 2Report a problem
- Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant TherapyActive, not recruitingNCT03700905Phase 3Report a problem
- Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based ChemotherapyActive, not recruitingNCT03670056Phase 2Report a problem
- Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)CompletedNCT03669523Phase 2Report a problem
- Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT03652233Phase 1Report a problem
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsActive, not recruitingNCT03650894Phase 2Report a problem
- Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerCompletedNCT03647969Phase 2Report a problem
- A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT03635892Phase 2Report a problem
- Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable OsteosarcomaActive, not recruitingNCT03628209Phase 1Report a problem
- DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBLActive, not recruitingNCT03620578Phase 2Report a problem
- A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and NeckCompletedNCT03620123Phase 2Report a problem
- Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgerySuspendedNCT03604991Phase 2/3Report a problem
- Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaActive, not recruitingNCT03604978Phase 1/2Report a problem
- Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03600155Phase 1Report a problem
- Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)CompletedNCT03591731Phase 2Report a problem
- Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue SarcomasCompletedNCT03590210Phase 2Report a problem
- Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid TumorsTerminatedNCT03585465Phase 1/2Report a problem
- Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin LymphomaCompletedNCT03580408Phase 2Report a problem
- Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular CarcinomaCompletedNCT03572582Phase 2Report a problem
- Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic CancerActive, not recruitingNCT03563248Phase 2Report a problem
- Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System LymphomaTerminatedNCT03558750Phase 1Report a problem
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerActive, not recruitingNCT03546686Phase 2Report a problem
- Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation TherapyCompletedNCT03543189Phase 1/2Report a problem
- Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular MelanomaActive, not recruitingNCT03528408Phase 2Report a problem
- Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLCActive, not recruitingNCT03527108Phase 2Report a problem
- Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid TumorsCompletedNCT03525925Phase 1Report a problem
- A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for ChemotherapyActive, not recruitingNCT03520491Phase 2Report a problem
- Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)CompletedNCT03510871Phase 2Report a problem
- Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer PatientsTerminatedNCT03509584Phase 1Report a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1Report a problem
- Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaActive, not recruitingNCT03502733Phase 1Report a problem
- Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancErCompletedNCT03469960Phase 3Report a problem
- Immunotherapy + Radiation in Resectable Soft Tissue SarcomaCompletedNCT03463408Early Phase 1Report a problem
- Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for RecurrenceActive, not recruitingNCT03443856Phase 2Report a problem
- Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal CancerTerminatedNCT03437200Phase 2Report a problem
- Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast CancerCompletedNCT03430479Phase 1/2Report a problem
- A Longitudinal Assessment of Tumor Evolution in Patients With Brain CancerCompletedNCT03425292Phase 1Report a problem
- A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell CancerCompletedNCT03416244Phase 2Report a problem
- Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric AdenocarcinomaCompletedNCT03409848Phase 2Report a problem
- Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast CancerCompletedNCT03409198Phase 2Report a problem
- Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapyCompletedNCT03387761Phase 1Report a problem
- Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular CarcinomaTerminatedNCT03382886Phase 1Report a problem
- Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma PatientsStatus unknownNCT03374839Phase 1/2Report a problem
- BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasActive, not recruitingNCT03355976Phase 2Report a problem
- Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC PatientsCompletedNCT03351361Phase 3Report a problem
- iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and IpilimumabActive, not recruitingNCT03350126Phase 2Report a problem
- A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's LymphomaCompletedNCT03343652Phase 1/2Report a problem
- Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer PatientsTerminatedNCT03342417Phase 2Report a problem
- Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)WithdrawnNCT03342352Phase 3Report a problem
- Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsActive, not recruitingNCT03333616Phase 2Report a problem
- Molecular Monitoring With Circulating Tumor DNA and Nivolumab MaintenanceCompletedNCT03311958Early Phase 1Report a problem
- Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCsStatus unknownNCT03311789Phase 1/2Report a problem
- Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryActive, not recruitingNCT03307616Phase 2Report a problem
- Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal CancerWithdrawnNCT03307603Phase 1/2Report a problem
- Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCLCompletedNCT03305445Phase 1Report a problem
- Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)CompletedNCT03299946Phase 1Report a problem
- Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)CompletedNCT03298893Phase 1/2Report a problem
- Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03297593Phase 2Report a problem
- TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanomaCompletedNCT03293784Phase 1Report a problem